UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported): May 3, 2019

 

CORINDUS VASCULAR ROBOTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware   001-37406   30-0687898

(State or Other

Jurisdiction of Incorporation)

  (Commission File Number)   (IRS Employer
Identification No.)

309 Waverley Oaks Road, Suite 105

Waltham, MA 02452

(Address of Principal Executive Office) (Zip Code)

 

 

Registrant's telephone number, including area code: (508) 653-3335

 Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock CVRS NYSE American

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indícate by check mark whether the registrant is an emerging growth Company as defined in Rule 405 of the Securities Act of 1933 (§ 230-405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On May 3, 2019, the stockholders of Corindus Vascular Robotics, Inc. (the “Company”), at the Company’s 2019 Annual Meeting of Stockholders (the “Annual Meeting”), considered and voted on three proposals, each of which was described in detail in the Company’s Proxy Statement. Of 207,076,671 shares of common stock eligible to vote as of the record date of March 20, 2019, 187,600,502 shares of common stock voted, in each case, on an as-converted to common stock for voting purposes basis, representing 90.59% of the voting power of all shares entitled to vote at the Annual Meeting, which represented a quorum for the Annual Meeting.

 

At the Annual Meeting, the stockholders voted on proposals to: (1) elect two directors to hold office for three-year terms, (2) approve by a non-binding advisory vote the compensation of the Company’s named executive officers as disclosed in the Proxy Statement, and (3) ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. More information on the proposals can be found in the Proxy Statement. 

 

Set forth below are the final voting results for each proposal submitted to a vote of the stockholders at the Annual Meeting. All results include the Common Stock and Series A Preferred Stock and Series A-1 Preferred Stock (in each case, on an as-converted-to-common-for-voting-purposes basis as described in the Proxy Statement).

 

Proposal 1:   To elect two nominees to serve as the Company’s Class III Directors to hold office for a three-year term or until their respective successors are elected and qualified.

  Nominee For Withheld Broker Non-Votes
  Jeffrey C. Lightcap 141,808,976 2,487,344 43,304,182
  Mark J. Toland 144,170,951 125,369 43,304,182

 

Proposal 2:   To approve by a non-binding advisory vote the compensation of the Company’s named executive officers as disclosed in the Proxy Statement (Say-on-pay).

 

  For Against Abstain Broker Non-Votes
  132,778,107 488,252 11,029,961 43,304,182

 

Proposal 3:   To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019.

 

  For Against Abstain Broker Non-Votes
  187,115,116 286,741 198,645 0

Each of the director nominees and proposals received the necessary votes in favor to be adopted by the Company’s stockholders at the Annual Meeting.

 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   
    CORINDUS VASCULAR ROBOTICS, INC.
   
   
Date:  May 8, 2019  

By:  

/s/ David W. Long

    David W. Long
      Chief Financial Officer

 

 
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Corindus Vascular Robotics Charts.
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Corindus Vascular Robotics Charts.